Related Experiment Videos

Controlled-release carvedilol in the management of systemic hypertension and myocardial dysfunction

William H Frishman1, Linda S Henderson, Mary Ann Lukas

  • 1Departments of Medicine and Pharmacology, New York Medical College/Westchester Medical Center, Valhalla, NY 10595, USA. william_frishman@nymc.edu

Vascular Health and Risk Management
|April 2, 2009
PubMed

Insights

Vasodilatory beta-blockers like carvedilol offer improved tolerability due to vasodilation. A new controlled-release formulation enhances convenience with once-daily dosing for cardiovascular disease management.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Cardiovascular disease is a leading global cause of mortality.
  • Beta-blockers are crucial in managing various cardiovascular conditions, including hypertension and post-myocardial infarction care.
  • Concerns exist regarding the first-line use and tolerability of traditional beta-blockers.

Purpose of the Study:

  • To review the clinical and pharmacologic data of controlled-release carvedilol.
  • To highlight the benefits of vasodilatory beta-blockers, specifically carvedilol.
  • To address the improved tolerability and convenience of a new controlled-release formulation.

Main Methods:

  • Review of existing clinical trial data.
  • Analysis of pharmacologic and hemodynamic properties of carvedilol.
  • Evaluation of data for a new controlled-release formulation.

Main Results:

  • Carvedilol combines beta-blockade with alpha 1-adrenergic receptor blockade, inducing vasodilation.
  • Vasodilation reduces total peripheral resistance, potentially improving tolerability.
  • A new controlled-release formulation of carvedilol offers once-daily dosing while maintaining clinical efficacy.

Conclusions:

  • Vasodilatory beta-blockers like carvedilol present an alternative with potentially better tolerability.
  • Controlled-release carvedilol provides a convenient once-daily option for cardiovascular disease management.
  • Further data supports the role of carvedilol, particularly its controlled-release form, in cardiovascular therapy.

Keywords:
beta-blockerscardiovascular diseaseheart failuremyocardial infarctionvasodilatory

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...